| scholarly article | Q13442814 |
| P356 | DOI | 10.1111/JDV.14053 |
| P698 | PubMed publication ID | 27859683 |
| P50 | author | Jacek Szepietowski | Q64681817 |
| P2093 | author name string | A Kuhn | |
| C Frances | |||
| M Caproni | |||
| F Nyberg | |||
| R Gläser | |||
| B Volc-Platzer | |||
| A Ranki | |||
| E Aberer | |||
| A Dreher | |||
| B Marinovic | |||
| A Landmann | |||
| H-W Klötgen | |||
| R Olteanu | |||
| Z Bata-Csörgő | |||
| P2860 | cites work | Peas, beans, and the Pythagorean theorem - the relevance of glucose-6-phosphate dehydrogenase deficiency in dermatology | Q46657452 |
| Severe cutaneous adverse drug reaction to leflunomide: a report of two cases | Q46710201 | ||
| Subacute cutaneous lupus erythematosus precipitated by leflunomide | Q46729928 | ||
| Leflunomide in subacute cutaneous lupus erythematosus - two sides of a coin | Q46824530 | ||
| A comparison of oral methylprednisolone plus azathioprine or mycophenolate mofetil for the treatment of bullous pemphigoid | Q46845242 | ||
| A trial of contraceptive methods in women with systemic lupus erythematosus | Q46851432 | ||
| Combined oral contraceptives in women with systemic lupus erythematosus | Q46851436 | ||
| The effect of methotrexate on improving serological abnormalities of patients with systemic lupus erythematosus. | Q50502906 | ||
| A case of generalized discoid lupus erythematosus: successful treatment with imiquimod cream 5%. | Q50713030 | ||
| Influence of smoking on disease severity and antimalarial therapy in cutaneous lupus erythematosus: analysis of 1002 patients from the EUSCLE database. | Q51150943 | ||
| Efficacy of tacrolimus 0.1% ointment in cutaneous lupus erythematosus: a multicenter, randomized, double-blind, vehicle-controlled trial. | Q51474220 | ||
| Monoclonal antibody against macrophage colony-stimulating factor suppresses circulating monocytes and tissue macrophage function but does not alter cell infiltration/activation in cutaneous lesions or clinical outcomes in patients with cutaneous lup | Q53343146 | ||
| Drug-related lupus. | Q53778499 | ||
| Efficacy and safety of methotrexate in recalcitrant cutaneous lupus erythematosus: results of a retrospective study in 43 patients. | Q53850772 | ||
| Mycophenolic acid-mediated suppression of human CD4+ T cells: more than mere guanine nucleotide deprivation | Q56899012 | ||
| European S3-Guidelines on the systemic treatment of psoriasis vulgaris | Q57244449 | ||
| Photosensitivity in cutaneous lupus erythematosus | Q26863253 | ||
| Effects of rituximab-based B-cell depletion therapy on skin manifestations of lupus erythematosus--report of 17 cases and review of the literature | Q27015934 | ||
| A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus | Q28254310 | ||
| Double-blind, randomized, controlled clinical trial of clofazimine compared with chloroquine in patients with systemic lupus erythematosus | Q28275253 | ||
| Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial | Q28304807 | ||
| EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics | Q33284736 | ||
| Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma | Q33344746 | ||
| Histopathology and immunohistochemistry of cutaneous lupus erythematosus after pulsed dye laser treatment | Q33912784 | ||
| Subacute cutaneous lupus erythematosus and its association with drugs: a population-based matched case-control study of 234 patients in Sweden. | Q34031291 | ||
| Pulsed dye laser as an excellent choice of treatment for lupus tumidus: a prospective study | Q34034899 | ||
| Dapsone and sulfones in dermatology: overview and update | Q34087357 | ||
| Revised recommendations on screening for chloroquine and hydroxychloroquine retinopathy | Q34162386 | ||
| Response to ustekinumab in a patient with both severe psoriasis and hypertrophic cutaneous lupus | Q34205687 | ||
| Cyclophosphamide for the treatment of systemic lupus erythematosus | Q34226984 | ||
| Cutaneous lupus after herpes zoster: isomorphic, isotopic, or both? | Q34284215 | ||
| Pimecrolimus 1% cream for cutaneous lupus erythematosus | Q34344494 | ||
| Dapsone in dermatology and beyond | Q34390020 | ||
| Drug-induced lupus: an update on its dermatologic aspects | Q34611958 | ||
| Mycophenolate mofetil for induction therapy of lupus nephritis: a systematic review and meta-analysis | Q34663885 | ||
| Drug insight: autoimmune effects of medications-what's new? | Q34736991 | ||
| The efficacy of pulsed dye laser treatment for inflammatory skin diseases: a systematic review | Q34742431 | ||
| Efficacy and safety of oral alitretinoin (9-cis retinoic acid) in patients with severe chronic hand eczema refractory to topical corticosteroids: results of a randomized, double-blind, placebo-controlled, multicentre trial | Q34753923 | ||
| Pediatric cutaneous lupus erythematosus treated with pulsed dye laser | Q35041706 | ||
| Low-dose thalidomide therapy for refractory cutaneous lesions of lupus erythematosus | Q35047657 | ||
| Cutaneous lupus erythematosus: diagnosis and management | Q35157482 | ||
| Efficacy of Intravenous Immunoglobulin Monotherapy in Patients with Cutaneous Lupus Erythematosus: Results of Proof-of-Concept Study | Q35289684 | ||
| Lupus erythematosus with leflunomide: induction or reactivation? | Q35554724 | ||
| Pimecrolimus 1% cream for the treatment of discoid lupus erythematosus | Q42667758 | ||
| Relationship between blood hydroxychloroquine and desethylchloroquine concentrations and cigarette smoking in treated patients with connective tissue diseases | Q42753835 | ||
| The use of low-dose cyclophosphamide followed by AZA/MMF treatment in childhood lupus nephritis | Q43281578 | ||
| A randomized controlled trial of R-salbutamol for topical treatment of discoid lupus erythematosus. | Q43291806 | ||
| Subacute cutaneous lupus erythematosus response to isotretinoin | Q43416693 | ||
| Treatment of resistant discoid lupus erythematosus of the palms and soles with mycophenolate mofetil | Q43652142 | ||
| Microinvasive squamous cell carcinoma arising in discoid lupus erythematosus lesions successfully treated with imiquimod 5% cream | Q43660280 | ||
| Benefits of leflunomide in systemic lupus erythematosus: a pilot observational study | Q43692733 | ||
| Isotretinoin for refractory lupus erythematosus | Q43771523 | ||
| Successful treatment of subacute cutaneous lupus erythematosus with mycophenolate mofetil | Q44051927 | ||
| Successful treatment of chronic discoid lupus erythematosus of the scalp with imiquimod | Q44224055 | ||
| Mycophenolate mofetil for the treatment of cutaneous lupus erythematosus with smoldering systemic involvement | Q44242521 | ||
| Ultraviolet light protection by a sunscreen prevents interferon-driven skin inflammation in cutaneous lupus erythematosus | Q44294024 | ||
| Thalidomide: Still an important second-line treatment in refractory cutaneous lupus erythematosus? | Q44443369 | ||
| Subacute cutaneous lupus erythematosus associated with leflunomide | Q44871900 | ||
| Thalidomide neurotoxicity: prospective study in patients with lupus erythematosus | Q44947244 | ||
| Double-blind, randomized, placebo-controlled pilot study of leflunomide in systemic lupus erythematosus | Q45088819 | ||
| Thalidomide for the treatment of resistant cutaneous lupus: efficacy and safety of different therapeutic regimens | Q45298403 | ||
| Efficacy of topical tacrolimus 0.3% in clobetasol propionate 0.05% ointment in therapy-resistant cutaneous lupus erythematosus: a cohort study. | Q45956776 | ||
| Lupus and pregnancy--15 years of experience in a tertiary center. | Q45967272 | ||
| Lower-dose thalidomide therapy effectively treats cutaneous lupus erythematosus but is limited by neuropathic toxicity. | Q46001895 | ||
| Pimecrolimus 1% cream versus betamethasone 17-valerate 0.1% cream in the treatment of facial discoid lupus erythematosus: a double-blind, randomized pilot study. | Q46003976 | ||
| Association of smoking with cutaneous manifestations in systemic lupus erythematosus. | Q46230713 | ||
| Leflunomide-induced subacute cutaneous lupus erythematosus. | Q46367693 | ||
| Hypertrophic lupus erythematosus treated successfully with acitretin as monotherapy | Q46618885 | ||
| Leflunomide-induced subacute cutaneous lupus erythematosus with erythema multiforme-like lesions | Q46643919 | ||
| Hydroxychloroquine: the cornerstone of lupus therapy | Q46643929 | ||
| Treatment of cutaneous lupus | Q35633324 | ||
| Response to antimalarial agents in cutaneous lupus erythematosus: a prospective analysis | Q35764302 | ||
| Tumour necrosis factor and other proinflammatory cytokines in systemic lupus erythematosus: a rationale for therapeutic intervention | Q35824493 | ||
| Lenalidomide therapy in treatment-refractory cutaneous lupus erythematosus: histologic and circulating leukocyte profile and potential risk of a systemic lupus flare | Q35836605 | ||
| Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial | Q35993027 | ||
| Methimazole-induced bullous systemic lupus erythematosus: a case report | Q36079081 | ||
| Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials | Q36302240 | ||
| The use of i.v. IG therapy in dermatology | Q36986054 | ||
| Lenalidomide for the treatment of resistant discoid lupus erythematosus | Q37335922 | ||
| Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review | Q37356697 | ||
| An update on the use of mycophenolate mofetil in lupus nephritis and other primary glomerular diseases | Q37378976 | ||
| Intravenous immunoglobulin in lupus panniculitis | Q37532010 | ||
| Cutaneous lupus erythematosus: Update of therapeutic options | Q37782472 | ||
| Cutaneous lupus erythematosus: update of therapeutic options part II. | Q37783662 | ||
| Efficacy of mycophenolate mofetil in antimalarial-resistant cutaneous lupus erythematosus | Q37884880 | ||
| Hypertrophic and ulcerated discoid lupus erythematosus | Q38059568 | ||
| Intravenous immune globulin in autoimmune and inflammatory diseases | Q38061484 | ||
| Therapeutic strategies evaluated by the European Society of Cutaneous Lupus Erythematosus (EUSCLE) Core Set Questionnaire in more than 1000 patients with cutaneous lupus erythematosus | Q38065665 | ||
| Immunologic and genetic considerations of cutaneous lupus erythematosus: a comprehensive review | Q38079068 | ||
| A consensus report on appropriate treatment optimization and transitioning in the management of moderate-to-severe plaque psoriasis. | Q38084325 | ||
| New biologic therapy for systemic lupus erythematosus. | Q38105715 | ||
| Comparison of serious adverse reactions between thalidomide and lenalidomide: analysis in the French Pharmacovigilance database | Q38146900 | ||
| Adherence to treatment in systemic lupus erythematosus patients | Q38163139 | ||
| Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study | Q38466691 | ||
| Dapsone as Second-Line Treatment for Cutaneous Lupus Erythematosus? A Retrospective Analysis of 34 Patients and a Review of the Literature. | Q38647377 | ||
| Advances in the treatment of cutaneous lupus erythematosus | Q38851093 | ||
| Pharmacokinetics, tolerability, and preliminary efficacy of paquinimod (ABR-215757), a new quinoline-3-carboxamide derivative: studies in lupus-prone mice and a multicenter, randomized, double-blind, placebo-controlled, repeat-dose, dose-ranging stu | Q39680831 | ||
| Photoprovocation in cutaneous lupus erythematosus: a multicenter study evaluating a standardized protocol. | Q39748743 | ||
| Recommendations on Screening for Chloroquine and Hydroxychloroquine Retinopathy (2016 Revision). | Q39907371 | ||
| Recombinant interferon alpha 2a is effective in the treatment of discoid and subacute cutaneous lupus erythematosus | Q40764591 | ||
| Systemic lupus erythematosus in three ethnic groups: XVI. Association of hydroxychloroquine use with reduced risk of damage accrual | Q41912319 | ||
| Effect of smoking on the effectiveness of antimalarial drugs for cutaneous lesions of patients with lupus: assessment in a prospective study | Q41913281 | ||
| Recommendations on screening for chloroquine and hydroxychloroquine retinopathy: a report by the American Academy of Ophthalmology | Q41917354 | ||
| The risk of toxic retinopathy in patients on long-term hydroxychloroquine therapy | Q41920001 | ||
| ANCA-positive lupus erythematodes profundus. Successful therapy with low dosage dapsone | Q41926211 | ||
| Clinical and pharmacogenetic influences on response to hydroxychloroquine in discoid lupus erythematosus: a retrospective cohort study. | Q41932343 | ||
| Discoid chronic lupus erythematosus at the site of a previously healed cutaneous leishmaniasis: an example of isotopic response | Q41935767 | ||
| Treatment of cutaneous lupus erythematosus with acitretin and hydroxychloroquine | Q41939243 | ||
| Possible induction of systemic lupus erythematosus by interferon-α treatment in a patient with a malignant carcinoid tumour | Q42099573 | ||
| Dose-related regulatory effect of intravenous immunoglobulin on dendritic cells-mediated immune response | Q42251007 | ||
| Thalidomide in the treatment of sixty cases of chronic discoid lupus erythematosus | Q42259263 | ||
| Mycophenolate sodium for subacute cutaneous lupus erythematosus resistant to standard therapy | Q42616372 | ||
| Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French AutoImmunity and Rituximab registry | Q42661986 | ||
| P433 | issue | 3 | |
| P921 | main subject | cutaneous lupus erythematosus | Q18553226 |
| P304 | page(s) | 389-404 | |
| P577 | publication date | 2016-11-15 | |
| P1433 | published in | Journal of the European Academy of Dermatology and Venereology | Q15760872 |
| P1476 | title | S2k guideline for treatment of cutaneous lupus erythematosus - guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV). | |
| P478 | volume | 31 |
| Q64989369 | A review of cutaneous lupus erythematosus: improving outcomes with a multidisciplinary approach. |
| Q64043005 | Advances in Cutaneous Lupus Erythematosus and Dermatomyositis: A Report from the 4th International Conference on Cutaneous Lupus Erythematosus-An Ongoing Need for International Consensus and Collaborations |
| Q92464993 | Cutaneous lupus erythematosus: A review of the literature |
| Q92535243 | Cutaneous lupus erythematosus: new insights into pathogenesis and therapeutic strategies |
| Q99610669 | European dermatology forum: Updated guidelines on the use of extracorporeal photopheresis 2020 - Part 2 |
| Q47567099 | High-dose intravenous immunoglobulins for the treatment of dermatological autoimmune diseases |
| Q49932309 | Hochdosierte intravenöse Immunglobuline bei dermatologischen Autoimmunerkrankungen |
| Q92625510 | Management strategies and future directions for systemic lupus erythematosus in adults |
| Q92404923 | Nucleic Acid Immunity in the Pathogenesis of Cutaneous Lupus Erythematosus |
| Q48332079 | The Cutaneous Spectrum of Lupus Erythematosus. |
| Q90106977 | Treatment of cutaneous lupus erythematosus: current approaches and future strategies |
Search more.